Life Sciences & Biotechnology
Title : | Ras Effector RASSF10 locks the metabolic reprogramming mechanism in tumour cells |
Area of research : | Life Sciences & Biotechnology |
Focus area : | Biotechnology |
Principal Investigator : | Prof. Sundarasamy Mahalingam,
Indian Institute of Technology(IIT) Madras |
Timeline Start Year : | 2023 |
Timeline End Year : | 2025 |
Contact info : | sundarmahalingam1964@gmail.com |
Details
Executive Summary : | Tumour development is a multistep process with different biological capabilities acquired at each stage. Deregulation in developmental pathways, including RAS, alters cell fate decisions. RASSF10, a member of novel nonenzymatic RAS effectors, is downregulated in 60% of cancers through hypermethylation. It inhibits cell proliferation, survival, and migration. RASSF10 downregulates GNL3L and IMPDH2 expression, which are overexpressed in many solid tumors and negatively correlate with patient survival. Understanding RASSF10's function is crucial for cancer treatment. |
Total Budget (INR): | 76,10,237 |
Organizations involved
